Hutchmed Share News (HCM)
HCM Share
HCM Share
HCM Share
HCM Share
HCM
HCM Share
HCM Level 2
HCM Live
HCM Broker
HCM Directors
HCM Financial
HCM
HCM Short
HCM
Last checked at -
(Sharecast News) - Hutchmed China announced the first commercial sale in China of 'Orpathys', or savolitinib, on Tuesday, which is its "oral, potent, and highly-selective" small molecule inhibitor of MET, a receptor tyrosine kinase.
Read more
TRADING UPDATES: Smiths gets Euros sticker boost; Hotel Chocolat grows
Read moreTRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays
Read moreTRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free
Read moreTRADING UPDATES: Topps Tiles improves as curbs ease; Bermele makes buy
Read moreIN BRIEF: Hutchmed launches global offering for 104 million shares
Read moreIN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China
Read moreIN BRIEF: Hutchmed launches Hong Kong IPO; drug candidate approved
Read more(Sharecast News) - Hutchmed China announced the launch of its Hong Kong public offering on Friday, as part of its global offering of 104 million new shares, proposing the primary listing of its ordinary shares on the main board of the Hong Kong Stock Exchange under the stock code '13'.
Read moreTRADING UPDATES: Cordiant deploys IPO funds; Scotgold gets loan
Read moreTRADING UPDATES: STV looks to summer's football; In The Style sales up
Read moreUK shareholder meetings calendar - next 7 days
Read moreIN BRIEF: Hutchison China gets USD100 million investment from Baring
Read moreIN BRIEF: Hutchison China starts first phase trials for HMPL-306
Read moreTRADING UPDATES: Arden Partners to return to annual profitability
Read more
Last checked at